Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial
Posted inGastroenterology news Oncology

Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial

A Phase II trial investigating the combination of cabozantinib and nivolumab in advanced extrapancreatic neuroendocrine tumors (epNETs) failed to meet its primary objective response rate endpoint, despite high rates of stable disease, highlighting the challenges of immunotherapy in these tumors.
Synergistic Potential and Hematologic Hurdles: Sapacitabine and Olaparib in BRCA1/2-Mutated Metastatic Breast Cancer
Posted innews Oncology

Synergistic Potential and Hematologic Hurdles: Sapacitabine and Olaparib in BRCA1/2-Mutated Metastatic Breast Cancer

A Phase Ib study of sapacitabine and olaparib in gBRCA-mutated metastatic breast cancer showed a 50% objective response rate and 9.7-month median PFS. While significant hematological toxicities limited dose escalation, the combination demonstrated durable clinical benefit and provided key insights into resistance mechanisms.
Palbociclib, Trastuzumab, and Endocrine Therapy Significantly Extend Progression-Free Survival in PAM50 Luminal HER2-Positive Advanced Breast Cancer: Results from the SOLTI-1303 PATRICIA Trial
Posted innews Oncology

Palbociclib, Trastuzumab, and Endocrine Therapy Significantly Extend Progression-Free Survival in PAM50 Luminal HER2-Positive Advanced Breast Cancer: Results from the SOLTI-1303 PATRICIA Trial

The Phase II SOLTI-1303 PATRICIA trial (Cohort C) demonstrates that a triplet regimen of palbociclib, trastuzumab, and endocrine therapy significantly improves progression-free survival compared to physician's choice treatments in pretreated patients with HER2-positive, PAM50 luminal subtype advanced breast cancer.